Triciribine (NSC 154020)

For research use only.

Catalog No.S1117 Synonyms: VD-0002, vqd-002, API-2, TCN

30 publications

Triciribine (NSC 154020) Chemical Structure

CAS No. 35943-35-2

Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 150 In stock
USD 120 In stock
USD 170 In stock
USD 570 In stock
USD 1670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Triciribine (NSC 154020) has been cited by 30 publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
Targets
HIV-1 [2]
(CEM-SS, H9, H9IIIB, U1 cells)
Akt [1]
(PC3 cells)
20 nM 130 nM
In vitro

Triciribine exhibits maximum growth inhibition around 1-10 μM and inhibits phosphorylation of Akt, as well as downstream p70S6K, to basal levels at 100μM (IC50 = 130 nM). Triciribine shows particular promise for inhibiting growth in Nf1 and Trp53 mutant astrocytoma cells in a grade-dependent manner. The WHO II K1861-10 line is inhibited, incompletely (69% maximum inhibition), with a GI50 value of 1.7 μM for Triciribine, whereas higher-grade tumor lines (KR158, KR130, and SF295) are inhibited to a greater extent (>80% maximum inhibition) at lower GI50 values (0.4–1.1 mM). Importantly, Triciribine is much less effective at inhibiting primary astrocytes (GI5013.6 mM), suggesting that this inhibitor may show specificity for tumor cells. [1] Triciribine inihibits HIV-1with an IC50 of 20 nM. Greater than 90% inhibition is achieved at 0.1μM and complete inhibition of syncytia formation is achieved at 5μM. Associated cell toxicity in the same cell line for Triciribine is 46 μM, resulting in selectivity indices of 2250. Triciribine markedly inhibits HIV-1-induced p24 core antigen production, reverse transcriptase, and infectious virus production in a dose-dependent manner using HIV-1 acutedly infected CEM-SS, H9, and persistently infected H9III B and U1 cells. [2] Triciribine inhibits Akt phosphorylation at Thr308 and Ser473 and Akt activity in the human prostate cancer cell line PC-3. Triciribine sensitizes PC-3 cells to TRAIL- and anti-CD95-induced apoptosis, whereas the cells remain resistant to DNA damaging chemotherapeutics. [3] Triciribine is highly selective for Akt and does not inhibit the activation of phosphatidylinositol 3-kinase, phosphoinositide-dependent kinase-1, protein kinase C, serum and glucocorticoid-inducible kinase, protein kinase A, signal transducer and activators of transcription 3, extracellular signal-regulated kinase-1/2, or c-Jun NH2-terminal kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 MoHjSpVv[3Srb36gZZN{[Xl? MliyWIV{fGWmIHnuJJZqfHKxIH\vdkBkgXSxdH;4bYNqfHliYXfhbY5{fCCvdYLpcoUhVDF{MUCgcIV2c2WvaXOgZ4VtdHNuIFnDOVA:OC5yM{ZOwG0> NXm5bHNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC4PFI{PzFpPkGwPFgzOzdzPD;hQi=>
HFF MYPGeY5kfGmxbjDhd5NigQ>? NFLRVmRJS02YIIDsZZF2\SCjc4PhfUB4[XNicHXy[o9zdWWmIIXzbY5oKEiIRjDj[YxteyCjbnSg[YZn\WO2IIfhd{Bk[WyldXzheIVlKGG|IHGgdIVz[2WwdHHn[UBw\iC{ZXT1Z5Rqd25iaX6gcpVu[mW{IH;mJJBt[XG3ZYOsJGlEPTB;Mj61{txO NH;3[FA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEi4NlM4OSd-MUC4PFI{PzF:L3G+
BSC-1 NYmwR4ZiSW62aY\pdoFtKGG|c3H5 Ml;nRY51cX[rcnHsJIFkfGm4aYT5JJdieyC2ZYP0[YQhfXOrbnegZY4h\W68eX3lMYxqdmunZDDpcY12dm:|b4Li[Y51KGG|c3H5JEhGVEmVQTmgeI8h\GW2ZXP0JGhUXi1zIDjo[ZJx\XNic3ntdIxmgCC4aYL1d{B1gXCnIEGpJJV{cW6pIFLTR{0yKGOnbHzzMEBKSzVyPUKz{txO Ml;FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB6OEKzO|EoRjFyOEiyN|cyRC:jPh?=
HFF MXrBcpRqfmm{YXygZZN{[Xl? MUnBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIR21XKHejczDk[ZRmem2rbnXkJIJ6KHCuYYH1[UBz\WS3Y4Tpc44h[XO|YYmgeZNqdmdiSF\GJINmdGy|LDDJR|UxRTJwNd88US=> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODh6MkO3N{c,OTB6OEKzO|M9N2F-
AA2 M2TRfWZ2dmO2aX;uJIF{e2G7 M1rLUVUhcHK| MYPJcpRz[WOnbHz1cIFzKHCqb4PwbI9zgWyjdHnvckApOTByIIXNLUBqdiC3bnnu[oVkfGWmIFHBNkBk\WyuczD3ZZMhe3S3ZHnl[EBi\nSncjC1JIhzeyCxZjDJcoN2[mG2aX;uMkwhS2:wY3XueJJifGmxbk25{txO MoXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB6OEKzO|MoRjFyOEiyN|c{RC:jPh?=
BSC-1 MoLaRY51cX[rcnHsJIF{e2G7 M1rn[2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhUXi1zIIfhd{Bl\XSncn3pcoVlKHW|aX7nJGJUSy1zIHPlcIx{KGK7IHHuJIVvgnmvZT3sbY5s\WRiaX3teY5we2:{YnXueEBie3OjeTCoSWxKW0FrLDDJR|UxRTJ|zszN MkjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB6OEKzO|MoRjFyOEiyN|c{RC:jPh?=
Huh-7 MnzRSpVv[3Srb36gZZN{[Xl? NEPqZXhEd22yb4Xu[EB4[XNidHXzeIVlKG[xcjDpeJMh[WKrbHn0fUB1dyCrbnjpZol1KGincHH0bZRqeyCFII\pdoFtKFKQQTDy[ZBtcWOjdHnvckBqdiCKdXitO{Bk\WyuczCobJVu[W5iaHXwZZRwdWFiY3XscJMqNCCHQ{WwQVLPxE1? NHLne4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUG3O|Q3PCd-MUWxO|c1PjR:L3G+
MCF7 MY\DfZRwfG:6aXPpeJkh[XO|YYm= MnLCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9NE4xPc7:TR?= MmTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
MCF7 M1:4XmN6fG:2b4jpZ4l1gSCjc4PhfS=> M1Hjd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMhcW5icILld4Vv[2Vib3[gNVAhfU1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSUWwQVAvPTcQvF2= NF3lPJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
MDA-MB-231 NF7LZmNEgXSxdH;4bYNqfHliYYPzZZk> NX;UO3h2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9NE43Qc7:TR?= NG\sNm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
MCF7 MlvER5l1d3SxeHnjbZR6KGG|c3H5 M1THVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTNwNkVOwG0> NYX6e4l3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
MDA-MB-468 MW\DfZRwfG:6aXPpeJkh[XO|YYm= NVrmVoZIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9NVAvOjoQvF2= MoDqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
184B5 M1vMfGN6fG:2b4jpZ4l1gSCjc4PhfS=> Moj2NlAhfU1? M17UWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFE5PEJ3IHPlcIx{KGG2IEKwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l3ME2xOk46Ps7:TR?= NWL1ZnV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
MDA-MB-468 MYHDfZRwfG:6aXPpeJkh[XO|YYm= M1;MXlExKHWP NUT5WHI2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9NlAvPDYQvF2= Mle4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
184B5 MlG2R5l1d3SxeHnjbZR6KGG|c3H5 MlHsNVAhfU1? NYTHU3Z3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOTh2QkWgZ4VtdHNiYYSgNVAhfU1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSUWwQVM1|ryP NH22dYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
MDA-MB-231 NWDCOWFHS3m2b4TvfIlkcXS7IHHzd4F6 NGL5[WQyOCC3TR?= M1zGRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMUCgeW0h[2iub4LvdZVqdmViYomgV3JDKGG|c3H5MEBIUTVyPUO3{txO MoSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
184B5 NEf4OW1EgXSxdH;4bYNqfHliYYPzZZk> MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxPFRDPSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:PDEQvF2= NFTyeYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
MDA-MB-468 NYXFell{S3m2b4TvfIlkcXS7IHHzd4F6 MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHL5JHNTSiCjc4PhfUwhT0l3ME20N{42O87:TR?= M1GyWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
MDM MXHBcpRqfmm{YXygZZN{[Xl? MXi2JIRigXN? MnnpRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKEGGQTDpcoZm[3SnZDDpckBpfW2jbjDNSG0h[2WubIOgZZN{\XO|ZXSgZZMh\XiycnXzd4lwdiCxZjDwNlQh[W62aXflckBi\nSncjC2JIRigXNicH;zeIlv\mWldHnvckBjgSCHTFnTRUwhUUN3ME2wMlAxPs7:TR?= MofhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
ACH2 M2TweWN6fG:2b4jpZ4l1gSCjc4PhfS=> M3H1N2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGFEUDJiY3XscJMhcW6oZXP0[YQhf2m2aDDsZZRmdnRiSIXtZY4hcW2vdX7v[IVncWOrZX7jfUB3cXK3czCxJIJ6KE2WUzDhd5NigSxiQ1O1NF0xNjBzzszN M1T3e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
ACH2 NE[0b4FEgXSxdH;4bYNqfHliYYPzZZk> MojOR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRWNJOiClZXzsd{Bqdm[nY4Tl[EB4cXSqIHzheIVvfCCKdX3hckBqdW23bn;k[YZq[2mnbnP5JJZqenW|IEGgZpkhVVSVIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJJR2dW:{IH7lZ5Jwe2m|IH\hZ5RweiCjbIDoZUwhS0N3ME2wMlAy|ryP M{HNUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
CEM-SS NYjIR3JFSW62aY\pdoFtKGG|c3H5 NICxXWo3KGSjeYO= NEfNT3lCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gR2VONVOVIHPlcIx{KGmwZnXjeIVlKHerdHigNE44QCC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDlfJBz\XO|aX;uJI9nKHB{NDDhcpRq\2WwIHHmeIVzKDZiZHH5d{Bxd3O2aX7m[YN1cW:wIHL5JGVNUVODLDDJR|UxRDBwMEJOwG0> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
MDM MXPBcpRqfmm{YXygZZN{[Xl? MV22JIRigXN? M2\OSmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCEQVygbY5n\WO2ZXSgbY4hcHWvYX6gUWROKGOnbHzzJIF{e2W|c3XkJIF{KGW6cILld5Nqd25ib3[gdFI1KGGwdHnn[Y4h[W[2ZYKgOkBl[Xm|IIDvd5Rqdm[nY4Tpc44h[nliRVzJV2EtKEmFNUC9NE4xOTkQvF2= MkLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
H9 MlH1RY51cX[rcnHsJIF{e2G7 NY\qNIs2SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIGPLNUBqdm[nY4Tl[EBqdiCqdX3hckBJQSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIGLleoVze2VidILhcpNkemmydHHz[UBjgSCdM1jdWHRRKGmwY3;ydI9z[XSrb36gZZN{[XluIFnDOVA:OC5yM{dOwG0> NXqzXYx1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
CEM-SS MoDQRY51cX[rcnHsJIF{e2G7 NE\N[IJCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1Kg[ZhxemW|c3nu[{Bv\WZicILveIVqdiCrbn\lZ5RqdmdiaX6gR2VONVOVIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{YXygVoV3\XK|ZTD0doFve2O{aYD0ZZNmKGK7IGuzTH1VXFBiaX7jc5Jxd3KjdHnvckBie3OjeTygTWM2OD1yLkC0{txO NH;FUXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
CEM-SS NUCybHBmSW62aY\pdoFtKGG|c3H5 MVHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iQ1XNMXNUKGOnbHzzJIlv\mWldHXkJJdqfGhiMD63PEB2VCCxZjD2bZJ2eyC|dH;jb{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIGLleoVze2VidILhcpNkemmydHHz[UBjgSCdM1jdWHRRKGmwY3;ydI9z[XSrb36gZZN{[XluIFnDOVA:OC5yON88US=> M3rQS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
H9 M4LG[WFvfGm4aYLhcEBie3OjeR?= MV;BcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iSEmgZ4VtdHNiaX7m[YN1\WRid3n0bEAzPSC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJHJmfmW{c3WgeJJidnOlcnnweIF{\SCkeTDbN2heXFSSIHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTB:MD6x{txO MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
H9 M4S5T2FvfGm4aYLhcEBie3OjeR?= NG\Me2hCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gTFkh[2WubIOgbY5n\WO2ZXSge4l1cCBzMj61JJVNKG:oII\pdpV{KHO2b3PrJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxiUnX2[ZJ{\SC2cnHud4NzcXC2YYPlJIJ6KFt|SG3UWHAhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NFwxNjIQvF2= MlK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
H9 NGfYVpFCdnSrdnnyZYwh[XO|YYm= Mlr5RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIFi5JINmdGy|IHnu[oVkfGWmIIfpeIghPi5{NTD1UEBw\iC4aYL1d{B{fG:lazDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKFKndnXyd4UhfHKjboPjdolxfGG|ZTDifUBcO0ifVGTQJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUC8NE4y|ryP Mk\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
H9 NUjKWWU5SW62aY\pdoFtKGG|c3H5 MUO2JIRigXN? MULBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iSEmgZ4VtdHNiaX7m[YN1\WRid3n0bEAyOi53IIXMJI9nKH[rcoXzJJN1d2OtIHHzd4V{e2WmIHHzJIV5eHKnc4Ppc44hd2ZicEK0JIFvfGmpZX6gZYZ1\XJiNjDkZZl{KHCxc4TpcoZm[3Srb36gZpkhTUyLU1GsJGlEPTB:MD6x{txO M3HxS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
H9 MVfBcpRqfmm{YXygZZN{[Xl? M1fMb|Yh\GG7cx?= NITnbXdCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gTFkh[2WubIOgbY5n\WO2ZXSge4l1cCB4LkK1JJVNKG:oII\pdpV{KHO2b3PrJIF{e2W|c3XkJIF{KGW6cILld5Nqd25ib3[gdFI1KGGwdHnn[Y4h[W[2ZYKgOkBl[Xm|IIDvd5Rqdm[nY4Tpc44h[nliRVzJV2EtKEmFNUC8NE4y|ryP Ml7mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
CEM-SS NIPGfYNCdnSrdnnyZYwh[XO|YYm= MWrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhW0tzIHnu[oVkfGWmIHnuJIh2dWGwIFPFUU1UWyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIGLleoVze2VidILhcpNkemmydHHz[UBjgSCdM1jdWHRRKGmwY3;ydI9z[XSrb36gZZN{[XluIFnDOVA:OC5zM988US=> NEHVOG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
ACH2 MXHBcpRqfmm{YXygZZN{[Xl? M4PCUlMh\GG7cx?= NWnEbYk2SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhPSC6IEGwK|Mh[2WubIOve4VtdCCKdX3hckBqdW23bn;k[YZq[2mnbnP5JJZqenW|IEGgbY5n\WO2ZXSgbY4hcHWvYX6gRWNJOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIGLleoVze2VidILhcpNkemmydHHz[UBi\nSncjCzJIRigXNiYomgX|NJZVSWUDDpcoNwenCxcnH0bY9vKGG|c3H5JIlvKHC{ZYPlcoNmKG:oIEWgcocwdWxidIXtc5IhdmWlcn;zbZMh\mGldH;yJIFteGijLDDJR|UxRTBwMUZOwG0> MnLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
AA5 NFTveFVCdnSrdnnyZYwh[XO|YYm= M2HmbWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JI9nKEi3bXHuJIludXWwb3Tl[olkcWWwY4mgeolzfXNiMTCzRkBqdm[nY4Tl[EBqdiCDQUWgZ4VtdHNiaX7m[YN1\WRid3n0bEA{NjF|IIXMJI9nKH[rcoXzJJN1d2OtIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhWmW4ZYLz[UB1emGwc3PybZB1[XOnIHL5JHs{UF2WVGCgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MEywMlE4|ryP NGXCXYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
AA5 NV;i[pZmSW62aY\pdoFtKGG|c3H5 NHPHNmFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBw\iCKdX3hckBqdW23bn;k[YZq[2mnbnP5JJZqenW|IEGgN2IhcW6oZXP0[YQhcW5iQVG1JINmdGy|IHnu[oVkfGWmIIfpeIghOS53NjD1UEBw\iC4aYL1d{B{fG:lazDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKFKndnXyd4UhfHKjboPjdolxfGG|ZTDifUBcO0ifVGTQJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUC8NE4yP87:TR?= MlS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
AA5 M{nnWmFvfGm4aYLhcEBie3OjeR?= MUHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDv[kBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hSUF3IHPlcIx{KGmwZnXjeIVlKHerdHigNE44QCC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJHJmfmW{c3WgeJJidnOlcnnweIF{\SCkeTDbN2heXFSSIHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTB:MD6xO:69VQ>? NFq0eZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
CEM-SS M3zWd2FvfGm4aYLhcEBie3OjeR?= NWXmeYIzPiCmYYnz MVHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iQ1XNMXNUKGOnbHzzJIlv\mWldHXkJJdqfGhiMT61OkB2VCCxZjD2bZJ2eyC|dH;jb{Bie3Onc4Pl[EBieyCneIDy[ZN{cW:wIH;mJJAzPCCjboTp[4VvKGGodHXyJFYh\GG7czDwc5N1cW6oZXP0bY9vKGK7IFXMTXNCNCCLQ{WwQVAvOToQvF2= M{e4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
CEM-SS MojURY51cX[rcnHsJIF{e2G7 NH73SXJCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiaHHyZo9zcW6pIIDsZZNucWRiTly0MVMhcW6oZXP0[YQhcW5iQ1XNMXNUKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxiUnX2[ZJ{\SC2cnHud4NzcXC2YYPlJIJ6KFt|SG3UWHAhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NF0xNjMQvF2= NYCxd5NoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
U1 NFjqdnZCdnSrdnnyZYwh[XO|YYm= M4D5dGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCrbn\lZ5Rm\CCrbjDoeY1idiCXMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJHJmfmW{c3WgeJJidnOlcnnweIF{\SCkeTDbN2heXFSSIHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTB;MD6yN:69VQ>? M4rBfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
CEM-SS NVfVUIF6SW62aY\pdoFtKGG|c3H5 MmjoOkBl[Xm| NGixU3RCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gR2VONVOVIHPlcIx{KGmwZnXjeIVlKHerdHigN{4yOyC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDlfJBz\XO|aX;uJI9nKHB{NDDhcpRq\2WwIHHmeIVzKDZiZHH5d{Bxd3O2aX7m[YN1cW:wIHL5JGVNUVODLDDJR|UxRTBwMkVOwG0> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
U1 MnHHR5l1d3SxeHnjbZR6KGG|c3H5 MkL0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVEh[2WubIOgbY5n\WO2ZXSge4l1cCCuYYTlcpQhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIHL5JG1VWyCjc4PhfUwhS0N3ME2wMlI5|ryP NX\oN|c3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
U1 NG\jTpNEgXSxdH;4bYNqfHliYYPzZZk> NFTzPWtEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOSClZXzsd{Bqdm[nY4Tl[EB4cXSqIHzheIVvfCCKdX3hckBqdW23bn;k[YZq[2mnbnP5JJZqenW|IEGgZpkhVVSVIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJJR2dW:{IH7lZ5Jwe2m|IH\hZ5RweiCjbIDoZUwhS0N3ME2wMlI5|ryP NVXUVVdqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
CEM-SS MknlRY51cX[rcnHsJIF{e2G7 NIS3PXNCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gR2VONVOVIHPlcIx{KGmwZnXjeIVlKHerdHigNU42PiC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJHJmfmW{c3WgeJJidnOlcnnweIF{\SCkeTDbN2heXFSSIHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTB;MD6yPe69VQ>? M2rKOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
CEM-SS NWrZU5czSW62aY\pdoFtKGG|c3H5 MWHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iQ1XNMXNUKGOnbHzzJIlv\mWldHXkJJdqfGhiMz6xN{B2VCCxZjD2bZJ2eyC|dH;jb{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIGLleoVze2VidILhcpNkemmydHHz[UBjgSCdM1jdWHRRKGmwY3;ydI9z[XSrb36gZZN{[XluIFnDOVA:OC5|zszN NH;DNlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
CEM-SS Mkj6RY51cX[rcnHsJIF{e2G7 M2\BU2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCGMTDoZZJjd3KrbnegWJlzOTJ5SHnzJI12fGG2aX;uJIlvKG6nZjDwdo91\WmwIHnu[oVkfGmwZzDpckBETU1vU2OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBT\X[ncoPlJJRz[W6|Y4LpdJRie2ViYomgX|NJZVSWUDDpcoNwenCxcnH0bY9vKGG|c3H5MEBKSzVyPUCuN|PPxE1? M3;2dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
CEM-SS NH3USZhCdnSrdnnyZYwh[XO|YYm= NELkTYNCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiQUegbIFz[m:{aX7nJHR6ejF{N1jpd{BufXSjdHnvckBqdiCwZX[gdJJwfGWrbjDpcoZm[3SrbnegbY4hS0WPLWPTJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhWmW4ZYLz[UB1emGwc3PybZB1[XOnIHL5JHs{UF2WVGCgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3ME2wMlXPxE1? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
MDM Ml72R5l1d3SxeHnjbZR6KGG|c3H5 Mn76R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWROKGOnbHzzJIlv\mWldHXkJJdqfGhiSIXtZY4hcW2vdX7v[IVncWOrZX7jfUB3cXK3czCxJGJCVCCkeTDNWHMh[XO|YYmsJHREPTB;MD62Ou69VQ>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
CEM-SS NX;1dXVESW62aY\pdoFtKGG|c3H5 NUj1fG1XSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyB{IGLPSEBqdm[nY4Tl[EBqdiCqdX3hckBETU1vU2OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBT\X[ncoPlJJRz[W6|Y4LpdJRie2ViYomgX|NJZVSWUDDpcoNwenCxcnH0bY9vKGG|c3H5MEBKSzVyPUGuOO69VQ>? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
H9 NUXZXGk5SW62aY\pdoFtKGG|c3H5 NX\4c2ZkSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIEPCJIlv\mWldHXkJIlvKGi3bXHuJGg6KGOnbHzzJIlv\mWldHXkJJdqfGhiNUCgeWwhd2ZidnnyeZMhe3SxY3ugZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCCUZY\ldpNmKHS{YX7zZ5JqeHSjc3WgZpkhYzOKXWTUVEBqdmOxcoDvdoF1cW:wIHHzd4F6NCCLQ{WwQVEvPTQQvF2= Mk\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
H9 M4[2fWN6fG:2b4jpZ4l1gSCjc4PhfS=> NV;qdIFNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDliY3XscJMh[nliTWTTJIF{e2G7LDDJR|UxRTF4LkROwG0> MoewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
H9 MVHDfZRwfG:6aXPpeJkh[XO|YYm= NX;vW4JoS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDliY3XscJMh[nliTWTTJIF{e2G7LDDDR|UxRTF7LkdOwG0> MmfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PUMA / p-FoxO3a / p-AKT ; 

PubMed: 20978166     


p53-KO cells were treated with the AKT inhibitor triciribine (1 μM) or MK-2206 (25 μM) for 1 hr (for analysis of p-FoxO3a and p-AKT) or 24 hr (for analysis of PUMA), and indicated proteins were analyzed by Western blotting.

20978166
Immunofluorescence
TRF2 / 53BP1 ; 

PubMed: 23862686     


TIF analysis of HTC75 cells serum starved (0.01% FBS) for 16 h or treated with triciribine (1µM) for 3 hours. Cells were immunostained with anti-53BP1 (red) and TRF2 (green) antibodies. DMSO-treated cells were used as controls. Arrows indicate overlapping foci. 

23862686
In vivo 1 mg/kg/day i.p. treated Triciribine inhibits OVCAR3, OVCAR8 and PANC1 tumor growth, which overexpressing Akt, by 90%, 88% and 80% in nude mice, respectively. However, Triciribine has little effect on the growth of OVCAR5 and COLO357 cells. [4]

Protocol

Kinase Assay:[1]
- Collapse

Akt Phosphorylation Changes Assay:

Cells are grown to 80%–90% confluency and stimulated for 5–10 minutes with 1–10 ng/mL of epidermal growth factor or platelet derived growth factor (PDGF)–AA with or without 10–20 mM of U0126 or LY-294002. Protein lysates (5–20 μg) are separated by 12%–15% SDS PAGE and analyzed by Western blot for Akt, phosphorylated Akt (phospho-Ser 473), MAPK, and phosphorylated MAPK (p44/42 phospho-Thr202/Tyr204) antibodies (1:1000).
Cell Research:[2]
- Collapse
  • Cell lines: CEM-SS cells
  • Concentrations: 0-500 μM
  • Incubation Time: 48 hours
  • Method: Triciribine is evaluated for cytotoxicity by seeding CEM-SS cells at a density of 1 × 104 cells/well in growth medium, using a 96-well flat-bottom plate. Serial fivefold dilutions of Triciribine are prepared in growth medium and added to the wells as a second overlay. After a 48-hours incubation at 37 °C, the cells are pulse labeled with [3H]dThd (1 μCi per well, specific activity 20 Ci/mmol) for 6 hours and the cells are harvested to measure total DNA synthesis.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: OVCAR3, OVCAR8, PANC1, OVCAR5 and COLO357 tumor cells are injected s.c. into 80week-old female nude mice.
  • Dosages: 1 mg/kg/day
  • Administration: Triciribine is administrated through i.p. injection once a day.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 64 mg/mL (199.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 320.3
Formula

C13H16N6O4

CAS No. 35943-35-2
Storage powder
in solvent
Synonyms VD-0002, vqd-002, API-2, TCN
Smiles CN1C2=NC=NC3=C2C(=CN3C4C(C(C(O4)CO)O)O)C(=N1)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02987127 Unknown status -- Mucosa-Associated Lymphoid Tissue Lymphoma National Taiwan University Hospital February 2016 --
NCT00642031 Completed Drug: Triciribine Hematologic Malignancies|Leukemia Prescient Therapeutics Ltd.|VioQuest Pharmaceuticals August 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Triciribine (NSC 154020) | Triciribine (NSC 154020) supplier | purchase Triciribine (NSC 154020) | Triciribine (NSC 154020) cost | Triciribine (NSC 154020) manufacturer | order Triciribine (NSC 154020) | Triciribine (NSC 154020) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID